Dexamethasone decreases plasma levels of the prochiral fenbendazole and its chiral and achiral metabolites in sheep

Xenobiotica

Volumn 33, Issue 7, 2003, Pages 731-742

  Sanchez S ^a   Small, J ^b   Jones, D G ^b   McKellar, Q A ^b  

^a UNIVERSIDAD NACIONAL DEL CENTRO DE LA PROVINCIA DE BUENOS AIRES   (Argentina)

^b MOREDUN RESEARCH INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; BIOCHEMICAL MARKER; DEXAMETHASONE; DEXAMETHASONE ISONICOTINATE; DRUG METABOLITE; FENBENDAZOLE; OXFENDAZOLE; OXFENDAZOLE SULFONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHIRALITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG SCREENING; DRUG STRUCTURE; FEMALE; LIVER FUNCTION; NONHUMAN; PH; SHEEP; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ANIMALS; DEXAMETHASONE; DRUG INTERACTIONS; FEMALE; FENBENDAZOLE; INJECTIONS, INTRAMUSCULAR; ISOMERISM; METABOLIC CLEARANCE RATE; SHEEP;

ANIMALIA; OVIS ARIES;

EID: 10744228959     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/0049825031000089119     Document Type: Article

References (31)

1. ALVAREZ, L, SÁNCHEZ, S. and LANUSSE, C., 1997, Modified plasma and abomasal disposition of albendazole in nematode-infected sheep. Veterinary Parasitology, 69, 241-253.
2. BENCHAOUI, H. and MCKELLAR, Q., 1996, Interaction between fenbendazole and piperonyl butoxide: pharmacokinetic and pharmacodynamic implications. Journal of Pharmacy and Pharmacology, 48, 753-759.
3. BENOIT, E., BESSE, S. and DELATOUR, P., 1992, Effect of repeated doses of albendazole on enantiomerism of its sulphoxide metabolite in goats. American Journal of Veterinary Research, 53, 1663-1665.
4. BERETTA, C., FADIN, L., MALVISI STRACCIARI, J. and MONTESISSA, C., 1987, In vitro Febantel transformation by sheep and cattle ruminal fluids and metabolism by hepatic subcellular fractions from different animal species. Biochemical Pharmacology, 36, 3107-3114.
5. CAMPBELL, W. and HALUSHKA, P., 1996, Lipid derived autacoids, eicosanoids and platelets-activity factors. In J. G. Hardman, A. G. Gilman and L. E. Limbird (eds), Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th edn (New York: McGraw-Hill), pp. 601-616.
6. CRISTOFOL, C., VIRKEL, G., ALVAREZ, L., SANCHEZ, S., ARBOIX, M. and LANUSSE, C., 2001, Albendazole sulphoxide enantiomeric ratios in plasma and target tissues after intravenous administration of ricobendazole to cattle. Journal of Veterinary Pharmacology and Therapeutics, 24, 117-124.
7. DELATOUR, P., BENOIT, E., GARNIER, F. and BESSE, S., 1990, Chirality of the sulphoxide metabolites of fenbendazole and albendazole in sheep. Journal of Veterinary Pharmacology and Therapeutics, 13, 361-366.
8. GALTIER, P., ALVINERIE, M. and DELATOUR, P., 1986, In vitro sulfoxidation of albendazole by ovine liver microsomes: assay and frequency of various xenobiotics. American Journal Veterinary Research, 47, 447-450.
9. GIBALDI, M. and PERRIER, D., 1982, Pharmacokinetics, 2nd edn (New York: Marcel Dekker), pp. 45-109.
10. GOKBULUT, C., NOLAN, A. and MCKELLAR, Q., 2002, Plasma disposition, faecal excretion and in vitro metabolism of oxibendazole following oral administration in horses. Research in Veterinary Science, 72, 11-15.
11. HENNESSY, D., ALÍ, D. and SILINCE, J., 1995, The effect a short-term reduction in feed on the phamacokinetics and efficacy of albendazole in sheep. Australian Veterinary Journal, 72, 29-30.
12. JUNG, H., HURTADO, M., MEDINA, T., SÁNCHEZ, M. and SOTELO, J., 1990, Dexamethasone increases plasma levels of albendazole. Journal of Neurology, 237, 279-280.
13. LANUSSE, C., NARE, B. and PRICHARD, R., 1993, Comparative sulphoxidation of albendazole by sheep and cattle liver microsomes and the inhibitory effect of methimazole. Xenobiotica, 23, 285-295.
14. LANUSSE, C. and PRICHARD, R., 1993, Clinical pharmacokinetics and metabolism of benzimidazole anthelmintics in ruminants. Drug Metabolism Review, 25, 235-279.
15. LIN, J., CHIBA, M. and BAILLIE, T., 1999, Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacological Reviews, 51, 135-157.
16. MCKELLAR, Q., GALBRAITH, E. and BAXTER, P., 1993, Oral absorption and bioavailability of fenbendazole in the dog and the effects of concurrent ingestion of food. Journal of Veterinary Pharmacology and Therapeutics, 13, 223-227.
17. MCKELLAR, Q. A., GOKBULUT, C., MUZANDU, K. and BENCHAOUI, H., 2002, Fenbendazole pharmacokinetics, metabolism and potentiation in horses. Drug Metabolism and Disposition, 30, 1230-1239.
18. MONOSTORY, K. and VERECZKEY, L., 1994, The effect of phenobarbital and dexamethasone co-administration on the activity of rat liver P-450 system. Biochemical and Biophysical Research Communications, 203, 351-358.
19. MURRAY, M., HUDSON, A. and YASSA, V., 1992, Hepatic microsomal metabolism of the anthelmintic benzimidazole fenbendazole: enhanced inhibition of cytochrome P450 reactions by oxidized metabolites of the drug. Chemical Research Toxicology, 5, 60-66.
20. SÁNCHEZ, S., ALVAREZ, L. and LANUSSE, C., 1996, Nutritional condition affects the disposition kinetics of albendazole in cattle. Xenobiotica, 26, 307-320.
21. SÁNCHEZ, S., ALVAREZ, L. and LANUSSE, C., 1997, Fasting induced changes on the pharmacokinetic behaviour of albendazole and its metabolites in cattle. Journal of Veterinary Pharmacology and Therapeutics, 20, 38-47.
22. SÁNCHEZ, S., ALVAREZ, L., PIS, A., QUIROGA, M. and LANUSSE, C., 1999, Differences on the plasma and abomasal fluid kinetics of albendazole and its metabolites in calves grazed in pasture or fed a grain based diet. Research in Veterinary Science, 66, 223-230.
23. SÁNCHEZ, S., ALVAREZ, L., SALLOVITZ, J. and LANUSSE, C., 2000, Enhanced plasma and target tissues availabilities of albendazole and its metabolites in fasted calves: evaluation of different fasting intervals. Journal of Veterinary Pharmacology and Therapeutics, 23, 193-201.
24. SÁNCHEZ, S., JONES, D. G., SMALL, J. and MCKELLAR, Q. A., 2002, Intravenous racemic and chiral pharmacokinetic behaviour of oxfendazole co-administered with piperonyl butoxide in sheep. Journal of Veterinary Pharmacology and Therapeutics, 25, 7-14.
25. SOTELO, J. and JUNG, H., 1998, Pharmacokinetic optimisation of the treatment of neurocysticercosis. Clinical Pharmacokinetics, 34, 503-515.
26. SOUHAILI-EL AMRI, H., MOTHE, O., TOTIS, M., MASSON, C., BATT, A., DELATOUR, P. and SIEST, G., 1988, Albendazole sulfonation by rat liver cytochrome P-450c. Journal of Pharmacology and Experimental Therapeutics, 246, 758-764.
27. TAKAYANAGUI, O., LANCHOTE, V., MARQUES, M. and BONATOR, P., 1997, Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulphoxide with dexamethasone. Therapeutic Drug Monitoring, 19, 51-55.
28. VIRKEL, G., 2001, Biotransformación hepática y extra-hepática de fármacos benzimidazoles en rumiantes. PhD thesis, Universidad Nacional del Centro de la Provincia de Buenos Aires, Argentina.
29. VIRKEL, G., LIFSCHITZ, A., PIS, A. and LANUSSE, C., 2002, In vitro ruminal biotransformation of benzimidazole sulphoxide anthelmintics: enantioselective sulphoreduction in sheep and cattle. Journal of Veterinary Pharmacology and Therapeutics, 25, 15-23.
30. YOSHINO, K., KATOH, N., TAKAHASHI, K. and YUASA, A., 1993, Possible involvement of protein kinase C with induction of haptoglobin in cows by treatment with dexamethasone and by starvation. American Journal of Veterinary Research, 54, 689-694.
31. ZIEGLER, D., 1989, S-oxygenases in chemistry and biochemistry. In L. A. Damani (ed.), Sulphur-containing Drugs and Related Organic Compounds, vol. 2, part A (Chichester: Ellis Horwood), pp. 53-66.